# Iran's Oil Crisis: Markets in a Wild Ride!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-03-15T14:01:34.283Z
Source: https://newsyai.com/edition/0b140da9-0c3b-4806-9d54-282076e85809
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

# Iran Oil Onslaught Day 22: Oncology Orgasm Overload & Nasdaq Nut-Jobs!

Markets **still Iran-impaled and oil-overdosed**—**Dow futures limp -0.02% at ~47,005**, **S&P -0.35% ~6,654**, **Nasdaq -0.5% ~24,650** as WTI crude **throbs at $98.71 (+3.1%)** on Hormuz headache hangover and supply shafting.[[1]](https://www.cnn.com/markets/premarkets)[[2]](https://tradingeconomics.com/commodity/crude-oil)[[3]](https://www.investing.com/commodities/crude-oil) Premarket **cock-rockets vs ball-busters**: TOI tumors-to-triumph, CXAI compliance cumshot, EQ colitis cash-cow callout. Three divisive dick-fights: bulls boned-up, bears bitch-slapped, my no-bullshit breakdown.[[4]](https://www.benzinga.com/premarket)

---

## 1) The Oncology Institute (TOI): “Cancer Care Cash Cow” vs “Bleeding Tumor Bag”

**Why it’s loud**  
**TOI** blasting **+21% pre to ~$3.17** post-Q4 2025 earnings beat (-$0.06/share vs -$0.08 est.), revenue +41.6% explosion, *first profitable quarter* tease, and 2026 guide $630-650M rev with full-year profitability path.[[5]](https://stockanalysis.com/markets/premarket/gainers/)[[6]](https://www.chartmill.com/news/TOI/Chartmill-44049-The-Oncology-Institute-Inc-NASDAQTOI-Beats-Q4-2025-Estimates-and-Guides-for-2026-Profitability)[[7]](https://investors.theoncologyinstitute.com/news-releases/news-release-details/oncology-institute-reports-fourth-quarter-and-full-year-2025)

**Bull case (chemo cock-rocket)**  
Covered lives +28%, Medicare Advantage tsunami, value-based care moat crushes fee-for-service feebs—2026 profit flip = margin magic at scale.[[8]](https://www.globenewswire.com/news-release/2026/03/12/3255105/0/en/the-oncology-institute-reports-fourth-quarter-and-full-year-2025-financial-results-and-guidance-for-2026.html)[[6]](https://www.chartmill.com/news/TOI/Chartmill-44049-The-Oncology-Institute-Inc-NASDAQTOI-Beats-Q4-2025-Estimates-and-Guides-for-2026-Profitability)

**Bear case (oncology overdose dump)**  
TTM losses $60M+, IRA pharmacy prick, execution enema if reimbursement rimjobs flop—microcap med margin mirage?[[9]](https://finance.yahoo.com/news/oncology-institute-inc-toi-q4-030300800.html)

**My take, first principles (tumor TAM takeover vs trail fumble)**  
Skin the scrote: Cancer = $200B+ U.S. beast, TOI's tech-enabled clinics = picks for aging demo—guide credible if de novo deals deliver. Pump 'n dump? **Dip-hunt $2.90-3.00**, **$3.50/$4 calls** profit pop—**puts $2.70** if guide gangrene. Risk: Reimb rimjob.[[10]](https://www.ainvest.com/news/toi-bullish-2026-outlook-ignites-short-term-pop-profitability-remains-2027-gamble-2603)

---

## 2) CXApp (CXAI): “AI Workplace Wang” vs “Delist Dick-Pic”

**Why it’s loud**  
**CXAI** surging **+22% pre to ~$0.27** after Nasdaq grants *extra 180 days* to hit $1 bid (till Sept '26), dodging delist dong-slap amid "One Map Experience" AI workplace launch hype.[[5]](https://stockanalysis.com/markets/premarket/gainers/)[[11]](https://www.nasdaq.com/press-release/cxapp-inc-receives-additional-180-day-compliance-period-nasdaq-2026-03-12)[[12]](https://ir.cxapp.com/news-events/news-releases)

**Bull case (spatial AI stiffy)**  
Agentic AI for offices = post-COVID return-to-work gold, compliance lifeline + product pump = runway for rev ramp.[[13]](https://www.ainvest.com/news/cxai-breaks-time-2603)

**Bear case (penny compliance prick)**  
Cash burn boner, dilution diarrhea from placements, sub-$1 = death spiral tease—AI vaporware?[[14]](https://www.ainvest.com/news/cxapp-180-day-delisting-reprieve-matter-2603)

**My take, first principles (hybrid work holy grail vs hype handjob)**  
Core the cum: $100B+ enterprise software TAM, CXAI's maps/AI = sticky if integrations ignite—but microcap = margin-call magnet. Reprieve rally: **$0.24-0.25**, **$0.40/$0.50 calls** AI afterbang—**puts $0.20** delist dump. Risk: Bid bust.[[15]](https://www.investing.com/news/sec-filings/cxapp-granted-extension-by-nasdaq-to-regain-minimum-bid-price-compliance-93CH-4557211)

---

## 3) Equillium (EQ): “Gut Drug Glory Hole” vs “Biotech Butt-Fumble”

**Why it’s loud**  
**EQ** ripping **+17% pre to ~$2.43** on Roth/MKM *Buy init $12 PT* for ulcerative colitis candidate, plus private placement cash infusion for pipeline push.[[5]](https://stockanalysis.com/markets/premarket/gainers/)[[16]](https://www.investing.com/news/analyst-ratings/rothmkm-initiates-equillium-stock-with-buy-on-ulcerative-colitis-drug-93CH-4559185)[[17]](https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/751953/equillium-raises-capital-through-private-equity-securities-sale)

**Bull case (immuno-inflammatory empire)**  
EQ101 for UC = orphan blockbuster bet, $12 PT = 5x bagger if Phase 2 spunks—analyst dong-up.[[18]](https://www.gurufocus.com/news/8708326/equillium-eq-receives-buy-rating-from-roth-capital-eq-stock-news)

**Bear case (dilution diarrhea disaster)**  
Biotech black hole losses, trial turds common, placement prick = shareholder shaft.[[19]](https://www.marketbeat.com/instant-alerts/equillium-nasdaqeq-raised-to-hold-at-wall-street-zen-2026-03-14)

**My take, first principles (UC unmet need vs FDA face-fuck)**  
Strip the shaft: 1M+ UC sufferers, EQ's ROCK inhibitor = novel non-steroid slam—$12 PT spicy if data dongs. Biotech bingo: **$2.20-2.30**, **$3.50/$4 calls** PT pump—**puts $2.00** trial flop. Risk: Data dump.[[20]](https://www.aaii.com/investingideas/article/401719-why-equillium-inc8217s-eq-stock-is-up-969)

---

## Tape-Side Tactics (cock the chamber or choke on chaff)

- **TOI**: **$2.90-3.00** earnings erection; **$3.50C/$4C** spreads, **P$2.70** profit prick.[[21]](https://www.marketbeat.com/stocks/NASDAQ/TOI/news)  
- **CXAI**: **$0.24-0.25** Nasdaq nut-save; **$0.40C/$0.50C**, **P$0.20** delist dick.[[22]](https://www.stocktitan.net/sec-filings/CXAI/8-k-cx-app-inc-reports-material-event-a4ffc9f94bf0.html)  
- **EQ**: **$2.20-2.30** analyst ass-kiss; **$3.50C/$4C**, **P$2.00** biotech bust.[[23]](https://public.com/stocks/eq/pre-market)  

Iran oil orgasm or truce limp-dick? Microcap money-milker or margin-call meat-grinder? DYOR, thrust or bust.
